Glenmark Pharmaceuticals Intrinsic Value
GLENMARK Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1903.44 | ₹1522.75 - ₹2284.13 | -6.7% | EPS: ₹86.52, Sector P/E: 22x |
| Book Value Method | asset | ₹5098.00 | ₹4588.20 - ₹5607.80 | +150.0% | Book Value/Share: ₹3160.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4078.40 | ₹3670.56 - ₹4486.24 | +100.0% | Revenue/Share: ₹8862.86, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4078.40 | ₹3670.56 - ₹4486.24 | +100.0% | EBITDA: ₹4528.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2072.28 | ₹1657.82 - ₹2486.74 | +1.6% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹611.76 | ₹550.58 - ₹672.94 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1336.73 | ₹1203.06 - ₹1470.40 | -34.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4078.40 | ₹3670.56 - ₹4486.24 | +100.0% | ROE: 27.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2480.38 | ₹2232.34 - ₹2728.42 | +21.6% | EPS: ₹86.52, BVPS: ₹3160.36 |
Want to compare with current market value? Check GLENMARK share price latest .
Valuation Comparison Chart
GLENMARK Intrinsic Value Analysis
What is the intrinsic value of GLENMARK?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Glenmark Pharmaceuticals (GLENMARK) is ₹2480.38 (median value). With the current market price of ₹2039.20, this represents a +21.6% variance from our estimated fair value.
The valuation range spans from ₹611.76 to ₹5098.00, indicating ₹611.76 - ₹5098.00.
Is GLENMARK undervalued or overvalued?
Based on our multi-method analysis, Glenmark Pharmaceuticals (GLENMARK) appears to be trading below calculated value by approximately 21.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.53 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.81 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 27.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.55x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Glenmark Pharmaceuticals
Additional stock information and data for GLENMARK
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-828 Cr | ₹-828 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-265 Cr | ₹-265 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹625 Cr | ₹368 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,109 Cr | ₹951 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,131 Cr | ₹800 Cr | Positive Free Cash Flow | 8/10 |